Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | GMNN | O75496 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | THPO | P40225 | 1/20 | 0.65 |
| ▸ | MTOR | P42345 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 17/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carboxynaphthol SCHEMBL462270 | 0.88 | ADRB2 (0.78) | ADRB2KDM4EMEN1TP53CYP3A4 | |
| SCHEMBL4637281 | 0.87 | ADRB2 (0.80) | ADRB2KDM4EMEN1TP53CYP3A4 | |
| Alcohol SCHEMBL17728039 | 0.84 | ADRB2 (0.78) | ADRB2KDM4EMEN1TP53CYP3A4 | |
| SCHEMBL17728040 | 0.79 | ADRB2 (0.78) | ADRB2KDM4EMEN1TP53CYP3A4 | |
| Salmeterol SCHEMBL19211132 | 0.79 | ADRB2 (1.00) | ADRB2KDM4EMEN1TP53CYP3A4 | |
| Salmeterol SCHEMBL9806070 | 0.79 | ADRB2 (1.00) | ADRB2KDM4EMEN1TP53CYP3A4 | |
| Salmeterol SCHEMBL18070 | 0.79 | ADRB2 (1.00) | ADRB2KDM4EMEN1TP53CYP3A4 | |
| Salmeterol SCHEMBL2833182 | 0.79 | ADRB2 (1.00) | ADRB2KDM4EMEN1TP53CYP3A4 | |
| Salmeterol SCHEMBL29372524 | 0.79 | ADRB2 (1.00) | ADRB2KDM4EMEN1TP53CYP3A4 | |
| Salmeterol SCHEMBL29352164 | 0.79 | ADRB2 (1.00) | ADRB2KDM4EMEN1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4992474-A | Adrenergic stimulants | GLAXO GROUP LTD. (GB) | 1991-02-12 | — | — | US | claimed |
| EP-1937626-B1 | Process and intermediates for the preparation of Salmeterol | GENERICS UK LTD (GB) | 2016-02-17 | — | — | EP | disclosed |
| US-8648214-B2 | Processes suitable for the preparation of salmeterol | GENERICS [UK] LIMITED (GB) | 2014-02-11 | — | — | US | disclosed |
| US-8648214-B2 | Processes suitable for the preparation of salmeterol | GENERICS [UK] LIMITED (GB) | 2014-02-11 | — | — | US | disclosed |
| EP-2641893-A1 | PROCESS FOR THE PREPARATION OF SALMETEROL AND ITS SALTS | Generics [UK] Limited (GB) | 2013-09-25 | — | — | EP | disclosed |
| EP-2641893-A1 | PROCESS FOR THE PREPARATION OF SALMETEROL AND ITS SALTS | Generics [UK] Limited (GB) | 2013-09-25 | — | — | EP | disclosed |
| US-20080262267-A1 | NOVEL PROCESS | GENERICS [UK] LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080262267-A1 | NOVEL PROCESS | GENERICS [UK] LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1937626-A1 | NOVEL PROCESS | Merck Generics (UK) Limited (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007045857-A1 | NOVEL PROCESS | GENERICS (UK) LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262267-A1 | NOVEL PROCESS | CYP4A11, HSD3B1, HSD11B1 | ADRB2 128/4885KDM4E 396/4885MEN1 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.